[HTML][HTML] Case report: sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for …
F Baldi, C Dentone, M Mikulska, D Fenoglio… - Frontiers in …, 2023 - frontiersin.org
COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with
the host immune system and the role of therapy still remains only partly understood. There …
the host immune system and the role of therapy still remains only partly understood. There …
[HTML][HTML] Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for …
F Baldi, C Dentone, M Mikulska, D Fenoglio… - Frontiers in …, 2022 - ncbi.nlm.nih.gov
COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with
the host immune system and the role of therapy still remains only partly understood. There …
the host immune system and the role of therapy still remains only partly understood. There …
Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
F Baldi, C Dentone, M Mikulska… - Frontiers in …, 2023 - pubmed.ncbi.nlm.nih.gov
COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with
the host immune system and the role of therapy still remains only partly understood. There …
the host immune system and the role of therapy still remains only partly understood. There …
[PDF][PDF] Aleksandra Barac, University of Belgrade, Serbia
D Firinu, R Carsetti, F Baldi, DR Giacobbe, F Baldi… - 2023 - scienceopen.com
There have been several advances among the available therapies for coronavirus disease
2019 (COVID-19), with the development of new oral antivirals and monoclonal antibodies (1 …
2019 (COVID-19), with the development of new oral antivirals and monoclonal antibodies (1 …
Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
F Baldi, C Dentone, M Mikulska, D Fenoglio… - Frontiers in …, 2022 - europepmc.org
COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with
the host immune system and the role of therapy still remains only partly understood. There …
the host immune system and the role of therapy still remains only partly understood. There …
[引用][C] Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for …
F Baldi, C Dentone, M Mikulska, D Fenoglio… - Frontiers in Medicine …, 2022 - jglobal.jst.go.jp
Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage
treatment option in two immunocompromised patients hospitalized for COVID-19 | Article …
treatment option in two immunocompromised patients hospitalized for COVID-19 | Article …
Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19 …
F Baldi, C Dentone, M Mikulska, D Fenoglio… - Frontiers in …, 2022 - europepmc.org
COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with
the host immune system and the role of therapy still remains only partly understood. There …
the host immune system and the role of therapy still remains only partly understood. There …